menu search

Site centers corp. (sitc) tops q4 ffo and revenue estimates

SITE CENTERS CORP. (SITC) delivered FFO and revenue surprises of 3.57% and 0.84%, respectively, for the quarter ended December 2022....

February 8, 2023, 9:47 am

Site centers (sitc) provides transaction activity update

SITE Centers (SITC) provides an update on its transaction activities for fourth-quarter 2022 and from the beginning of 2023 through Jan 9, 2023, which...

January 11, 2023, 9:47 am

Site centers (sitc) stock rallies 25.9% qtd: here's why

Solid leasing activity amid growing customers' preference for in-person shopping experience, healthy operating performance and capital-recycling moves...

December 30, 2022, 8:17 am

Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standa...

November 11, 2022, 5:00 pm

Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standa...

November 11, 2022, 5:00 pm

Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standa...

November 11, 2022, 5:00 pm

Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standa...

November 11, 2022, 5:00 pm

Predicine to introduce predicinecomplete™, its genome-wide liquid biopsy solution, at the society for immunotherapy of cancer (sitc) 37th annual meeting

SILICON VALLEY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Predicine, a global molecular insights company, announces the introduction of PredicineCOMP...

November 11, 2022, 2:00 am

Imugene’s oncarlytics combination with celularity’s placental-derived off-the-shelf allogeneic cycart-19 t cells preclinical data presented at sitc annual meeting

SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and C...

November 10, 2022, 10:00 pm

Bicycle therapeutics to present five posters highlighting preclinical data from its bicycle tumor-targeted immune cell agonist® (bicycle tica®) programs at the sitc 37th annual meeting

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated cla...

November 10, 2022, 9:09 am

Masonic cancer center, university of minnesota to present data in poster presentation from the phase 1 clinical trial to evaluate hcw9218 in solid tumors at the sitc 37th annual meeting

Presentation includes data on safety and dosage escalationand immune system reaction to HCW9218 No incidence of mucosal bleeding resulting from the HC...

November 8, 2022, 12:00 pm

Cytomx therapeutics to present preclinical data for conditionally activated interferon alpha-2b (cx-801) at the sitc 2022 annual meeting

- IND filing for CX-801 is anticipated in the second half of 2023 - - IND filing for CX-801 is anticipated in the second half of 2023 -...

November 7, 2022, 4:15 pm

Medivir to present data on additive efficacy of fostrox in combination with anti-pd1 in nonclinical tumor models at the sitc 2022 annual meeting

STOCKHOLM , Sept. 8, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments fo...

September 8, 2022, 3:33 am

Site centers corp. (sitc) upgraded to buy: here's what you should know

SITE CENTERS CORP. (SITC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Bu...

September 6, 2022, 1:32 pm

Site centers (sitc) refinances credit facility, stock up

SITE Centers (SITC) refinances its unsecured revolving credit facility of $950 million and upsizes its unsecured term loan facility to $200 million. I...

June 8, 2022, 12:48 pm

Site centers corp. (sitc) ceo, david lukes on q1 2022 results - earnings call transcript

SITE Centers Corp. (NYSE:SITC ) Q1 2022 Earnings Conference Call April 26, 2022 8:00 AM ET Company Participants Monica Kukreja - Capital Markets & Inv...

April 26, 2022, 2:29 pm

Site centers (sitc) q4 offo & revenues top estimates, noi up

SITE Centers' (SITC) Q4 results reflect better-than-anticipated revenues and operating FFO performance....

February 10, 2022, 4:54 pm

Site centers (sitc) q4 offo & revenues top estimates, noi up

SITE Centers' (SITC) Q4 results reflect better-than-anticipated revenues and operating FFO performance....

February 10, 2022, 4:54 pm

Site centers (sitc) q4 offo & revenues top estimates, noi up

SITE Centers' (SITC) Q4 results reflect better-than-anticipated revenues and operating FFO performance....

February 10, 2022, 4:54 pm

Site centers (sitc) ceo, david lukes on q4 2021 results - earnings call transcript

SITE Centers (SITC) CEO, David Lukes on Q4 2021 Results - Earnings Call Transcript...

February 9, 2022, 1:15 pm


Search within

Pages Search Results: